Companies House 11043800 2025-11-29 2025-11-29 2024-11-30 false iso4217:GBP xbrli:pure 11043800 2023-11-30 2024-11-29 11043800 2025-11-29 11043800 2024-11-30 2025-11-29 11043800 2024-11-29 11043800 curr:PoundSterling 2024-11-30 2025-11-29 11043800 uk-bus:CompanyLimitedByGuarantee 2024-11-30 2025-11-29 11043800 uk-bus:FRS102 2024-11-30 2025-11-29 11043800 uk-bus:AuditExempt-NoAccountantsReport 2024-11-30 2025-11-29 11043800 uk-bus:FullAccounts 2024-11-30 2025-11-29 11043800 uk-bus:RegisteredOffice 2024-11-30 2025-11-29 11043800 uk-bus:Director1 2024-11-30 2025-11-29 11043800 uk-bus:Director2 2024-11-30 2025-11-29 11043800 uk-bus:Director3 2024-11-30 2025-11-29 11043800 uk-bus:Director4 2024-11-30 2025-11-29 11043800 uk-bus:Director5 2024-11-30 2025-11-29 11043800 uk-bus:Director6 2024-11-30 2025-11-29 11043800 uk-bus:Director7 2024-11-30 2025-11-29 11043800 uk-bus:Director8 2024-11-30 2025-11-29 11043800 uk-bus:Director9 2024-11-30 2025-11-29 11043800 uk-bus:Director10 2024-11-30 2025-11-29 11043800 uk-bus:Director11 2024-11-30 2025-11-29 11043800 uk-bus:Director12 2024-11-30 2025-11-29 11043800 uk-bus:Director13 2024-11-30 2025-11-29 11043800 uk-bus:Director14 2024-11-30 2025-11-29 11043800 uk-bus:Director15 2024-11-30 2025-11-29 11043800 uk-bus:Director16 2024-11-30 2025-11-29 11043800 uk-bus:Director17 2024-11-30 2025-11-29 11043800 uk-bus:Director18 2024-11-30 2025-11-29 11043800 uk-bus:Director19 2024-11-30 2025-11-29 11043800 uk-bus:Director20 2024-11-30 2025-11-29 11043800 uk-bus:Director21 2024-11-30 2025-11-29 11043800 uk-bus:CompanySecretary1 2024-11-30 2025-11-29 11043800 core:AfterOneYear 2025-11-29 11043800 core:AfterOneYear 2024-11-29 11043800 core:WithinOneYear 2025-11-29 11043800 core:WithinOneYear 2024-11-29 11043800 core:WithinOneYear 2024-11-30 2025-11-29 11043800 core:AfterOneYear 2025-11-29 11043800 core:AfterOneYear 2024-11-29 11043800 core:AfterOneYear 2024-11-30 2025-11-29 11043800 core:ShareCapital 2025-11-29 11043800 core:ShareCapital 2024-11-29 11043800 core:SharePremium 2025-11-29 11043800 core:SharePremium 2024-11-29 11043800 core:OtherReservesSubtotal 2025-11-29 11043800 core:OtherReservesSubtotal 2024-11-29 11043800 core:RevaluationReserve 2025-11-29 11043800 core:RevaluationReserve 2024-11-29 11043800 core:RetainedEarningsAccumulatedLosses 2025-11-29 11043800 core:RetainedEarningsAccumulatedLosses 2024-11-29 11043800 1 2024-11-30 2025-11-29 11043800 2 2024-11-30 2025-11-29 11043800 3 2024-11-30 2025-11-29 11043800 core:LandBuildings 2024-11-30 2025-11-29 11043800 core:LandBuildings 2025-11-29 11043800 core:LandBuildings 2023-11-30 2024-11-29 11043800 core:LandBuildings 2024-11-29 11043800 core:PlantMachinery 2024-11-30 2025-11-29 11043800 core:PlantMachinery 2025-11-29 11043800 core:PlantMachinery 2023-11-30 2024-11-29 11043800 core:PlantMachinery 2024-11-29 11043800 core:FurnitureFittingsToolsEquipment 2024-11-30 2025-11-29 11043800 core:FurnitureFittingsToolsEquipment 2025-11-29 11043800 core:FurnitureFittingsToolsEquipment 2023-11-30 2024-11-29 11043800 core:FurnitureFittingsToolsEquipment 2024-11-29 11043800 core:OfficeEquipment 2024-11-30 2025-11-29 11043800 core:OfficeEquipment 2025-11-29 11043800 core:OfficeEquipment 2023-11-30 2024-11-29 11043800 core:OfficeEquipment 2024-11-29 11043800 core:Vehicles 2024-11-30 2025-11-29 11043800 core:Vehicles 2025-11-29 11043800 core:Vehicles 2023-11-30 2024-11-29 11043800 core:Vehicles 2024-11-29 11043800 core:NetGoodwill 2024-11-30 2025-11-29 11043800 core:NetGoodwill 2025-11-29 11043800 core:NetGoodwill 2023-11-30 2024-11-29 11043800 core:NetGoodwill 2024-11-29 11043800 core:IntangibleAssetsOtherThanGoodwill 2024-11-30 2025-11-29 11043800 core:IntangibleAssetsOtherThanGoodwill 2025-11-29 11043800 core:IntangibleAssetsOtherThanGoodwill 2023-11-30 2024-11-29 11043800 core:IntangibleAssetsOtherThanGoodwill 2024-11-29

# NEW DAWN THERAPIES CIC

## Company limited by guarantee

## Company Registration Number:
11043800 (England and Wales)

## Unaudited statutory accounts for the year ended 29 November 2025

## Period of accounts

## Start date: 30 November 2024

## End date: 29 November 2025

# NEW DAWN THERAPIES CIC

## Contents of the Financial Statements

for the Period Ended 29 November 2025

Directors report |
Profit and loss |
Balance sheet |
Additional notes |
Balance sheet notes |
Community Interest Report |

# NEW DAWN THERAPIES CIC

Directors' report period ended 29 November 2025

The directors present their report with the financial statements of the company for the period ended 29 November 2025

Directors

The directors shown below have held office during the whole of the period from
30 November 2024 to 29 November 2025

Richard William Palmer
Claire Wakefield

The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
24 April 2026

And signed on behalf of the board by:
Name: Claire Wakefield
Status: Director

# NEW DAWN THERAPIES CIC

## Profit And Loss Account

for the Period Ended 29 November 2025

| 2025 | 2024
--- | --- | ---
| £ | £
Turnover: | 75,465 | 71,830
Cost of sales: | ( 9,840 ) | ( 6,165 )
Gross profit(or loss): | 65,625 | 65,665
Administrative expenses: | ( 65,783 ) | ( 68,358 )
Operating profit(or loss): | (158) | (2,693)
Interest payable and similar charges: |  | ( 13 )
Profit(or loss) before tax: | (158) | (2,706)
Profit(or loss) for the financial year: | (158) | (2,706)

# NEW DAWN THERAPIES CIC

## Balance sheet

As at 29 November 2025

| Notes | 2025 | 2024
--- | --- | --- | ---
|  | £ | £
Fixed assets
Tangible assets: | 3 | 3,017 | 2,045
Total fixed assets: |  | 3,017 | 2,045
Current assets
Debtors: | 4 |  | 1,883
Cash at bank and in hand: |  | 4,580 | 6,141
Total current assets: |  | 4,580 | 8,024
Creditors: amounts falling due within one year: | 5 | ( 5,394 ) | ( 7,708 )
Net current assets (liabilities): |  | (814) | 316
Total assets less current liabilities: |  | 2,203 | 2,361
Total net assets (liabilities): |  | 2,203 | 2,361
Members' funds
Profit and loss account: |  | 2,203 | 2,361
Total members' funds: |  | 2,203 | 2,361

The notes form part of these financial statements

# NEW DAWN THERAPIES CIC

## Balance sheet statements

For the year ending 29 November 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 24 April 2026
and signed on behalf of the board by:

Name: Claire Wakefield
Status: Director

The notes form part of these financial statements

# NEW DAWN THERAPIES CIC

## Notes to the Financial Statements

for the Period Ended 29 November 2025

- ## 1. Accounting policies

  Basis of measurement and preparation

  These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

  Turnover policy

  Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

  Tangible fixed assets depreciation policy

  Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any Tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

# NEW DAWN THERAPIES CIC

## Notes to the Financial Statements

for the Period Ended 29 November 2025

- ## 2. Employees

  | 2025 | 2024
  --- | --- | ---
  Average number of employees during the period | 2 | 2

# NEW DAWN THERAPIES CIC

## Notes to the Financial Statements

for the Period Ended 29 November 2025

## 3. Tangible assets

| Land & buildings | Plant & machinery | Fixtures & fittings | Office equipment | Motor vehicles | Total
--- | --- | --- | --- | --- | --- | ---
Cost | £ | £ | £ | £ | £ | £
At 30 November 2024 |  |  | 1,846 | 2,580 |  | 4,426
Additions |  |  | 2,073 |  |  | 2,073
Disposals |  |  |  |  |  |
Revaluations |  |  |  |  |  |
Transfers |  |  |  |  |  |
At 29 November 2025 |  |  | 3,919 | 2,580 |  | 6,499
Depreciation |  |  |  |  |  |
At 30 November 2024 |  |  | 499 | 1,882 |  | 2,381
Charge for year |  |  | 587 | 514 |  | 1,101
On disposals |  |  |  |  |  |
Other adjustments |  |  |  |  |  |
At 29 November 2025 |  |  | 1,086 | 2,396 |  | 3,482
Net book value |  |  |  |  |  |
At 29 November 2025 |  |  | 2,833 | 184 |  | 3,017
At 29 November 2024 |  |  | 1,347 | 698 |  | 2,045

# NEW DAWN THERAPIES CIC

## Notes to the Financial Statements

for the Period Ended 29 November 2025

## 4. Debtors

| 2025 | 2024
--- | --- | ---
| £ | £
Trade debtors |  | 1,883
Total |  | 1,883

# NEW DAWN THERAPIES CIC

## Notes to the Financial Statements

for the Period Ended 29 November 2025

## 5. Creditors: amounts falling due within one year note

| 2025 | 2024
--- | --- | ---
| £ | £
Taxation and social security | 798 | 926
Other creditors | 4,596 | 6,782
Total | 5,394 | 7,708

# COMMUNITY INTEREST ANNUAL REPORT

### NEW DAWN THERAPIES CIC

### Company Number: 11043800 (England and Wales)

### Year Ending: 29 November 2025

Company activities and impact

The company’s activities are to provide accessible and affordable professional counselling and wellbeing services throughout the South West of England together with support for the professional community through the provision of professional training and development.

Consultation with stakeholders

No consultation with stakeholders

Directors' remuneration

£33,379 was paid.

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
30 April 2026

And signed on behalf of the board by:
Name: Claire Wakefield
Status: Director